NADPH oxidase gene therapy - Orchard Therapeutics

Drug Profile

NADPH oxidase gene therapy - Orchard Therapeutics

Alternative Names: Autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene - Genethon; Autologous CD34+cells transduced with the G1XCGD viral vector - Genethon; Chronic granulomatous disease gene therapy - Genethon; g1xcgd; G1XCGD transduced CD34+ cells; Lentiviral G1XCGD Gene Therapy - Genethon; Lentiviral vector transduced CD34+ cells; NADPH oxidase gene therapy - Genethon; OTL 102

Latest Information Update: 15 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genethon
  • Developer Genethon; University of California at Los Angeles
  • Class Gene therapies
  • Mechanism of Action Gene transference; Immunomodulators; NADPH oxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic granulomatous disease
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Chronic granulomatous disease

Most Recent Events

  • 05 Feb 2018 University of California at Los Angeles and Genethon re-initiate a phase I/II trial in Chronic granulomatous disease (in infants, In children, In adolescents, In adults) in USA (NCT02234934)
  • 15 Dec 2017 Orchard Therapeutics in-licenses NADPH oxidase gene therapy from Genethon
  • 10 Oct 2017 University of California at Los Angeles and Genethon suspended participant recruitment for a phase I/II trial in Chronic granulomatous disease (In children, In adolescents, In adults) in USA, for review of serious adverse event (NCT02234934)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top